Siglec-8 — Drug Target

All drugs that target Siglec-8 — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Bispecific antibody

Phase 2 pipeline (1)

• AK001 high dose · Allakos Inc. · Bispecific antibody · Immunology
  AK001 is a bispecific antibody that simultaneously engages Siglec-8 on eosinophils and mast cells while cross-linking them to trigger cell death and reduce type 2 inflammation.